Celerion’s clinical research operations in Belfast, Northern Ireland, have received authorization from the Medicines and Healthcare product Regulatory Agency (MHRA) to have importation of IMPs added to its manufacturing (MIA(IMP)) license. The license eliminates the need for a third party vendor to import IMPs on behalf of Celerion. According to the company, this saves time, costs, and initiates direct communication earlier with clients to expedite early-stage clinical studies. “The addition of...